Reviewed by Emily Henderson, B.Sc.Oct 23 2020 New research from Edith Cowan University (ECU) has revealed that training one arm can improve strength and decrease muscle loss in the other arm – without even moving it. The findings could help to address the muscle wastage and loss of strength often experienced in an immobilized arm,
Clinical Trials & Research
21 October 2020 — ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced the positive findings of a pooled analysis of COVID-19-related impacts across the investigational long-acting cabotegravir and rilpivirine clinical development programme. In the midst of the global pandemic, the analysis found
Reviewed by Emily Henderson, B.Sc.Oct 21 2020 Artificial light abnormally increases mosquito biting behavior at night in a species that typically prefers to bite people during the day, according to research from the University of Notre Dame that was published in The American Journal of Tropical Medicine and Hygiene. Increased biting by Aedes aegypti mosquitoes,
October 16, 2020 — The National Institutes of Health has launched an adaptive Phase 3 clinical trial to evaluate the safety and efficacy of three immune modulator drugs in hospitalized adults with COVID-19. Some COVID-19 patients experience an immune response in which the immune system unleashes excessive amounts of proteins that trigger inflammation — called
Reviewed by Emily Henderson, B.Sc.Oct 19 2020 The Columbia River is home to one of the West Coast’s most important Chinook salmon runs. Through late spring and early summer, mature fish return from the sea and begin their arduous journey upriver to spawn. In recent years, these fish have faced an additional challenge: hungry California
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) – Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather than by injection, today announced that the first subject has been dosed in its Phase 1 study of VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate. “We are advancing VXA-CoV2-1 into clinical development
Reviewed by Emily Henderson, B.Sc.Oct 16 2020 Rituals such as those centered around holidays and other celebrations play an important part in human relationships. When dating couples engage in rituals together, they learn more about each other. And those experiences can serve as diagnostic tools of where the relationship is going, a University of Illinois
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Oct. 13, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the initiation of a rolling submission to Health Canada for mRNA-1273, the Company’s vaccine candidate against COVID-19. This initiation follows positive results from a preclinical viral challenge study of
Reviewed by Emily Henderson, B.Sc.Oct 15 2020 To date, a few verified repeat SARS-CoV-2 infections have been documented around the world. Should reinfection [with SARS-CoV-2] prove commonplace, and barring a highly effective vaccine delivered to most of the world’s population, SARS-CoV-2 will likely become endemic.” Jeffrey Shaman & Marta Galanti, Department of Environmental Health Sciences,
October 13, 2020 — The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, today launched a study designed to determine whether certain approved therapies or investigational drugs in late-stage clinical development show promise against COVID-19 and merit advancement into larger clinical trials. The ACTIV-5 Big Effect Trial, which
Reviewed by Emily Henderson, B.Sc.Oct 13 2020 As vaccine trials progress and public health officials brace for a rise in COVID-19 cases, understanding how the body defends itself from SARS-CoV-2 infection is essential. New research, published in Clinical and Translational Immunology, provides a clearer picture of the protective antibodies induced by this virus and their
06 October 2020 — Vir Biotechnology, Inc. (Nasdaq: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the global expansion to Phase 3 of the COMET-ICE (COVID-19 Monoclonal antibody Efficacy Trial – Intent to Care Early) study evaluating VIR-7831 for the early treatment of COVID-19 in patients who are at high risk of hospitalization. VIR-7831 (also
Reviewed by Emily Henderson, B.Sc.Oct 9 2020 Rural emergency departments often lack the medical specialists who staff larger, urban hospitals. Yet rural patients have the same conditions–and need the same prompt care–that people in cities do. West Virginia University researcher Scott Findley has received a $1.2 million grant from the Health Resources and Services Administration–a
NEW YORK and MAINZ, GERMANY, October 6, 2020 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced the initiation of a rolling submission to the European Medicines Agency (EMA) for BNT162b2, the lead candidate from the companies’ vaccine development program against COVID-19. The EMA’s decision to start a rolling review follows the encouraging preliminary
Reviewed by Emily Henderson, B.Sc.Oct 9 2020 The University of Minnesota Medical School’s Department of Laboratory Medicine and Pathology has been selected to participate in a new national network dedicated to serological, or antibody, sciences as one of four Capacity Building Centers in the country. As part of the Serological Sciences Network (SeroNet), the team
NEW YORK & BRISBANE, Calif.–(BUSINESS WIRE) October 07, 2020 — Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. AFFINE is a global
Reviewed by Emily Henderson, B.Sc.Oct 7 2020 Researchers from the University of Iowa may have discovered a safe new way to manage blood sugar non-invasively. Exposing diabetic mice to a combination of static electric and magnetic fields for a few hours per day normalizes two major hallmarks of type 2 diabetes, according to new findings
THOUSAND OAKS, Calif., Oct. 5, 2020 /PRNewswire/ – Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC), who had failed a median of two prior lines of anti-cancer therapies (immunotherapy and/or chemotherapy). Sotorasib demonstrated an
Serological antibody immunoassays are one of the essential tools to combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In a new study, Immunoglobulin G (IgG) antibodies are detected in a large cohort, lasting up to 140 days. The researchers propose an alternative to reverse transcription-polymerase chain reaction (RT-PCR) positive status as a standard for
Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sep. 29, 2020– Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced the publication of the second interim analysis of the open-label Phase 1 study of mRNA-1273, its vaccine candidate against COVID-19, in The New
Oct 2 2020 Global glass primary packaging supplier SGD Pharma has expanded its ready-to-use (RTU) molded glass vial range to introduce a market-first 50ml volume option in tray developed at industrial scale by a molded glass manufacturer. The Sterinity platform, which includes both ISO and EasyLyo injectable vials, offers high-quality sterile Type I molded glass
Print this page SEATTLE, Sept. 29, 2020 /PRNewswire/ – CTI BioPharma Corp. (Nasdaq: CTIC) today announced that following a recent Pre-NDA meeting with the U.S. Food and Drug Administration (“FDA” or “the Agency”), the Company has reached an agreement to submit an NDA for the potential accelerated approval of pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia (platelet count